PRESS

RIS 2023 Program Agenda

HomeProgramRespiratory Innovation Summit ▶ RIS 2023 Program Agenda

ATS 2023 Respiratory Innovation Summit
Marriott Marquis Washington
901 Massachusetts Ave NW
Washington, DC 20001


Friday, May 19

1 p.m.

Registration Desk Open – Marriott Marquis Washington (Level M1) one level below street level

3 p.m. Poster Set Up Available
5 p.m. Networking Reception and Dinner – Posters Available
6 p.m.

Co-Chairs’ Welcoming Comments

  • Cecilia Gonzalo, MBA – Partner, Oberland Capital
  • Tim Watkins, MD, MS – Vice President, Clinical Development; Head – Fibrosis & Pulmonary Diseases - Inflammation Therapeutics, Gilead Sciences
6:10 p.m.

Pioneer Sponsor Address

  • Craig Conoscenti, MD, FCCP, ATSF – Therapeutic Area Head and Executive Director, Inflammation, Clinical Development and Medical Affairs Specialty, Boehringer Ingelheim Pharmaceuticals, Inc.

6:20 p.m.

RIS Keynote Address: Using the Apple Ecosystem for Health Research

  • Asha N. Chesnutt, MD – Clinical Specialist, Apple Health
  • Russell Bowler, MD, PhD – Professor of Medicine, National Jewish Health
6:40 p.m.

Panel: Patient Group Leaders from the ATS Public Advisory Roundtable

  • Moderator: Lyn Baranowski, MBA – Chief Executive Officer, Avalyn Pharma
  • Donna Appell, RN – Executive Director, Hermansky-Pudlak Syndrome Network
  • Michele Manion – Executive Director, PCD Foundation
  • Mary McGowan – Chief Executive Officer, Foundation for Sarcoidosis Research
  • Jennifer Mefford – Vice President, Corporate Partnerships, Pulmonary Fibrosis Foundation
  • Kari Luther Rosbeck – President and CEO, TSC Alliance
7:10 p.m. Featured Opportunities thru the NIH and HHS
  • NHLBI – Steve Flaim, PhD, FACC, FAHA – Senior Special Advisor & Investor-In-Residence, NHLBI, NIH NCATS
  • Joshua Fessel, MD, PhD - Senior Clinical Advisor, Division of Clinical Innovation; National Center for Advancing Translational Sciences (NCATS); NIH
  • NIH Foundation – Steve Hoffman, MS, BSc - Associate Vice President, Research Partnerships at Foundation for the National Institutes of Health
  • BARDA – Kimberly Armstrong, PhD, MT (ASCP)- Director, Influenza and Emerging Infectious Diseases Division (IEIDD), BARDA, ASPR, DHHS
7:30 p.m. Networking Reception and Poster Viewing
8:30 p.m. Adjourn

Saturday, May 20

7:15 a.m. Continental Breakfast – Posters Available
8 a.m.

Welcome from the ATS President

  • Gregory P. Downey, MD, ATSF - National Jewish Health
8:10 a.m.

Co-Chair Address: State of Innovation and Investment

  • Cecilia Gonzalo, MBA – Partner, Oberland Capital
  • Tim Watkins, MD, MS – Vice President, Clinical Development; Head – Fibrosis & Pulmonary Diseases - Inflammation Therapeutics, Gilead Sciences
8:30 a.m.

Showcase One: Asthma, COPD, and Airway Inflammation Innovators

  • Moderator: Ted Reiss, MD, MBE, ATSF
  • Avalo Therapeutics, Inc.
  • Kinaset Therapeutics
  • RAGE Biotech Pty Ltd
  • ReAlta Life Sciences
  • SpliSense
9 a.m.

Panel Discussion: Venture Capital

  • Moderator: Jamil Beg – Partner, 5AM Ventures
  • Tiba Aynechi, PhD – General Partner, Norwest Venture Partners
  • Christine Borowski, PhD – Vice President, Access Industries
  • Cristina Ghenoiu, PhD – Principal, RA Capital
  • Bert Kinsey, PhD, PharmD - Research Analyst, Principal - Eventide Asset Management
  • Maneka Mirchandaney – Principal, Viking Global Investors
  • Samantha Palmer, PhD, MBA - Executive Director, Business Development, Amgen Ventures
9:45 a.m. Networking Break – Posters Available
10:15 a.m.

Showcase Two: Critical Care, Chronic Cough and Sleep Innovators

  • Moderator: Courtney Crim, MD, ATSF
  • Apnimed
  • Atelerix Life Sciences
  • KeViRx, Inc.
  • Trevi Therapeutics
  • Xequel Bio, Inc.
10:45 a.m.

Fireside with the FDA: How Do We Accelerate Respiratory Discovery?

  • Moderator: Robert J. Meyer, MD – Principal, Greenleaf Health
  • Sally Seymour, MD – Office of Immunology and Inflammation - Division of Pulmonology, Allergy, and Critical Care (DPACC); US Food and Drug Administration
  • Mary Tran Than Hai, MD - Deputy Director for Clinical, Office of New Drugs; U.S. Food and Drug Administration
  • Onyeka Illoh, OD, MPH - Team Leader, Team Leader, Division of Clinical Outcome Assessment U.S. Food and Drug Administration
11:30 a.m.

Showcase Three: : Technology Innovators: Devices, Digital, AI and More

  • Moderator: Jason Kirkness, PhD, ATSF
  • FluidIQ
  • ImmuneIQ
  • Samay
  • Spiro Medical
  • VIDA
12 p.m. Lunch and Networking– Posters Available
1 p.m.

RIS Success Story Presentation - By Invitation

  • Peter M. Small, MD – Chief Medical Officer, Hyfe, Inc.
1:15 p.m.

Panel: Business Development

  • Moderator: Amanda Mason, PhD – Director, Business Development, Amgen
  • Jane Escott, PhD – Director, Respiratory Search and Evaluation Leader, AstraZeneca
  • Silke Hobbie, PhD – Global Head of Business Development & Licensing – Respiratory, Boehringer Ingelheim
  • Christopher Mortko, PhD, MBA - Vice President, Head Search and Evaluation, Business Development & Licensing, Merck
  • Eugene J. Sullivan, MD, FCCP – Chief Product Strategy Officer, Insmed
  • Jeannie Rojas, PhD, MBA – Senior Director, Worldwide Business Development - GlaxoSmithKline
  • Aryeh Fischer, MD - Clinical Development Lead, Lung Fibrosis, Bristol Myers Squibb
2 p.m.

Showcase Four: Inflammation, Infectious Disease and Other Innovators

  • Moderator: David Morris, MD
  • Aerami Therapeutics
  • Arrowhead Pharmaceuticals
  • AuraVax Therapeutics, Inc.
  • Rnatics
  • Synairgen
2:30 p.m. Networking Break - Posters Available
3 p.m.

Panel: Biomarkers and Innovation

  • Moderator: Tim Watkins, MD, MS - Vice President, Clinical Development; Head – Fibrosis & Pulmonary Diseases - Inflammation Therapeutics, Gilead Sciences
  • Bastiaan Driehuys, PhD –Chief Scientific Officer, Polarean Imaging
  • Jonathan G. Goldin, MD – Section Chief and Head of Radiology, UCLA Medical Center
  • Sydney B. Montesi, MD – Massachusetts General Hospital
  • Dave Morris, MD – President, Technologies and Therapeutics, Valo Health
  • John Sundy, MD, PhD – Chief Medical Officer and Head of Research and Development, Seismic Therapeutic
3:45 p.m.

Showcase Five: Fibrosis Innovators

  • Moderator: Mary Strek, MD
  • Atyr Pharma
  • Avalyn Pharmaceuticals
  • Lassen Therapeutics
  • Pieris Pharmaceuticals
  • Prosia
  • Vicore Pharma
4:15 p.m.

Closing Remarks and Sponsor Recognition

  • Cecilia Gonzalo, MBA – Partner, Oberland Capital
  • Tim Watkins, MD, MS - Vice President, Clinical Development; Head – Fibrosis & Pulmonary Diseases - Inflammation Therapeutics, Gilead Sciences
4:30 p.m. Networking Reception – Posters Available
6 p.m. Adjourn